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Abstract
T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase
inhibitors (TKI) for epidermal growth factor receptor (EGFR). Several third-generation EGFR mutant selective TKIs are
being explored to conquer this resistance. AZD9291 (osimertinib, tagrisso) has been approved for treatment of the
metastatic EGFR T790M mutation-positive non-small cell lung cancer. Resistance to AZD9291 has been described.
C797S mutation was reported to be a major mechanism for resistance to T790M-targeting EGFR inhibitors. This
review summarizes the latest development in identifying the C797S mutation and EAI045, the novel selective
inhibitor overcoming the C797S mutant.
Background
T790M mutation is the most common mechanism of re-
sistance to the first- and second-generation of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKI) [1]. Clinical trials are being done for several
T790M-targeting third-generation EGFR-TKIs [2, 3].
These inhibitors include AZD9291 (osimertinib, merele-
tinib, tagrisso), rociletinib (CO-1686), HM61713 (BI
1482694), ASP8273, EGF816, and PF-06747775 [4–10].
AZD9291 has been shown to have a response rate (RR)
of 61 % in EGFR T790M-positive non-small cell lung
cancer (NSCLC) patients [4, 10]. HM61713 at 800 mg/
day showed a 58.8 % response rate [5]. Unfortunately,
these lung cancer patients eventually developed resist-
ance to these drugs after 10 months. A better under-
standing of the mechanisms of resistance to these third-
generation EGFR inhibitors is critical for developing new
strategies to treat these patients [11]. EGFR Cys797Ser
(C797S) mutation, located within the tyrosine kinase
domain, was recently reported to be a potential mech-
anism of resistance to irreversible EGFR inhibitors such
as AZD9291, HM61713, WZ4002, and CO-1686 in
T790M-positive patients [12–16] (Fig. 1). This article
reviewed the latest development in identifying the
C797S mutation and other mechanisms of resistance.
C797S mediates resistance to AZD9291
In the first-in-human phase I/II AURA trial of
AZD9291, systemic progression in NSCLC patients was
seen after treatment for a median of 9.6 months [10].
Characterization of the mechanisms of resistance in 22
patients who became resistant to AZD9291 was reported
[12]. These patients with progression on AZD9291 in
the AURA trial had paired pre-treatment and post-
treatment plasma samples. Cell-free DNA (cfDNA) from
the plasma of these patients was analyzed by next-gene se-
quencing (NGS). All EGFR coding exons were analyzed
through a 20-gene panel. In the index case, an acquired
T→A mutation encoding an EGFR C797S mutation was
identified. In another case, an acquired C797S from G→
C mutation was documented. This group established a
Ba/F3 cell line harboring the C797S mutation and con-
firmed that the cell line was resistant to AZD9291.
Through the study of T790M-positive patients with ac-
quired resistance to AZD9291, three molecular subtypes
of AZD9291 resistance were revealed: T790M+/C797S+,
T790M+/C797S−, and T790M−/C797S−. The report also
discovered that in some cases, two different nucleotide
mutations (T to A and G to C) leading to C797S amino
acid mutation occurred in the same patients. Since only 6
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out of 15 cases acquired C797S mutation, additional
mechanisms of resistance to AZD9291 must be present.
In a separate case report, a female non-smoker with
widely metastatic lung adenocarcinoma progressed
through first-line chemotherapy and second-line erlo-
tinib [17]. She was found to have the EGFR 19 deletion
(del 19) and T790M at this point. She was enrolled in
the phase 1 AURA study of AZD9291 (NCT01802632)
and received AZD9291 for 9 months prior to disease
progression. Tumor biopsy at this juncture showed the
EGFR C797S mutation, in addition to the del 19 and
T790M. Under the strong selective pressure of EGFR-
TKIs, the tumor developed secondary T790M and ter-
tiary C797S mutations in the EGFR gene to bypass the
TKIs and maintain EGFR signaling.
C797S mutation mediates resistance to HM61713
HM61713 (BI 1482694) is another third-generation
EGFR inhibitor and covalently binds to a cysteine resi-
due near the kinase domain of mutant EGFR [18, 19]. In
a phase I/II study, HM61713 was shown to be active for
patients with T790M-positive NSCLC [5].
The first case report on resistance to HM61713 was
on a 57-year-old female never-smoker with stage IV lung
adenocarcinoma harboring EGFR del 19 [13]. The pa-
tient developed T790M mutation and became refractory
to gefitinib. She was enrolled into the trial of HM61713
and was progression free for 17 months. After progres-
sion, a repeat biopsy was performed and C797S mutation
was found in addition to T790M mutation and del 19.
Therefore, the tertiary acquired C797S mutation conferred
resistance to another third-generation EGFR TKI.
Exploration of mutations mediating resistance to
third-generation TKIs
To search for acquired resistance mutations in EGFR
gene, a group from Dana Farber Cancer Center utilized
site-directed mutagenesis in EGFR mutant Ba/F3 cell
lines harboring sensitizing mutations and/or T790M
[14]. The cells were then treated with third-generation
TKIs, WZ4002, CO-1686, and AZD9291. Resistant clones
were selected out, and mutations were characterized.
Three major resistant mutants were identified as EGFR
L718Q, L844V, and C797S. All of the three mutations
could cause resistance to both WZ4002 and CO-1686.
Only C797S mutation confers AZD9291 resistance. Most
interestingly, in the presence of del 19 or L858R and
T790M, C797S mutation leads to resistance to all current
EGFR inhibitors (gefitinib, afatinib, WZ4002, CO-1686,
and AZD9291), but L858R/T790M/C797S mutant re-
mains partially sensitive to cetuximab. It remains to be
determined whether cetuximab or cetuximab-based com-
binations are effective clinically in NSCLC patients that
develop the L858R/T790M/C797S mutant clone.
In a separate study, a cell line, MGH121, was established
from pleural effusion of a NSCLC patient who became re-
sistant to erlotinib [15]. This cell line was sensitive to the
third-generation TKIs, including WZ4002, CO-1686, and
Fig. 1 Clonal evolution of NSCLC cancer cells and mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. The T790M and
C797S mutations were highlighted in the EGFR sequence. Each colored ball represents a distinct clone. The number of balls in each group indi-
cates relative clonal size. NSCLC non-small cell lung cancer, EGFR epidermal growth factor receptor
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AZD9291. MGH121 cells were treated with increasing
doses of a third-generation TKI, WZ4002. This led to
MGH121 Res#1 which was resistant to third-generation
TKIs. C797S was found to be the acquired mutation.
When the L858R/T790M/C797S mutant construct was
stably expressed in MGH121, the cells became resistant to
all EGFR TKIs. The study explored further effect of the
presence of T790M and C797S together in the same allele
(i.e., cis) or in a different allele in the same cell (i.e., trans)
on the sensitivity to TKIs. It was clearly demonstrated in
the in vitro system that del19/T790M was resistant to the
second-generation TKIs, whereas del19/C797S was resist-
ant to the third-generation inhibitors. When T790M and
C797S were present in cis, the cells were resistant to all
EGFR TKIs. Therefore, characterization of mutation status
may guide clinical decision on therapeutic approaches.
HER2 and MET amplification mediates resistance
to AZD9291
Since some patients who progressed on AZD9291 were
negative for the C797S mutation, additional resistance
mechanisms must be present. In a case report, a 54-
year-old male with stage IV adenocarcinoma was found
to have acquired T790M mutation after progression
from second-line treatment with gefitinib [20]. The dis-
ease progressed after 12 months of AZD9291 treatment
on the AURA trial. HER2 amplification was identified
without C797S mutation from the tumor biopsy.
The second patient from the same report was a 60-
year-old female, a never-smoker, who was diagnosed
with stage IV adenocarcinoma with pleural metastasis
[20]. Mutation analysis revealed the known EGFR acti-
vating mutation in exon 21, L858R. She received erloti-
nib and gefitinib sequentially for 12 months. After
disease progression, T790M was identified by NGS and
she was treated with AZD9291 on the AURA trial [10].
She had partial tumor regression and remained progres-
sion free for 10 months. Re-biopsy of the AZD9291 re-
sistant tumor identified an EGFR activating mutation
and CMET amplification without T790M or C797S mu-
tation. These two cases indicated that in refractory
NSCLC without T790M or C797S mutations, additional
gene mutations or amplifications of tyrosine kinases other
than EGFR can be the mechanisms of resistance. Add-
itional treatment targeting the mutations will be needed.
EAI045, a fourth-generation selective inhibitor
overcoming EGFR C797S
Using purified EGFR mutant kinase peptide containing
L858R/T790M mutations, a library of approximately 2.5
million compounds were screened to search for selective
inhibitors against the kinase mutant [21]. EGFR allo-
steric inhibitor-1 (EAI001) was found to have such se-
lectivity toward the EGFR mutant. Further optimization
of this compound through medicinal chemistry yielded a
highly selective inhibitor, EAI045, toward L858R/T790M
mutant (IC50 = 3 nM). EAI045 was found to have a
1000-fold selectivity for the mutant versus wild-type
EGFR. The compound is an allosteric inhibitor, rather
than an ATP-competing agent. EAI045 was confirmed
to be highly selective against a panel of 250 protein kin-
ase peptides. However, EAI045 was not able to com-
pletely abolish EGFR autophosphorylation in H1975
NSCLC cell line harboring the L858R/T790M mutant.
Since EGFR dimerization is required for kinase enzyme
activation [22–24], the investigators hypothesized that
EAI045 was active against one subunit of an EGFR het-
erodimer/asymmetric dimer [21]. It was confirmed that
dimerization-defective/independent mutants were mark-
edly more sensitive to EAI045. When combined with
cetuximab that blocks EGFR dimerization [25], EAI045
markedly reduced tumor growth in a mouse model of
L858R/T790M—mutant-driven lung cancer. The mice
treated alone with EAI045 did not respond. EAI045 in
combination with cetuximab also induced marked tumor
shrinkage in the mouse model carrying L858R/T790M/
C797S, a mutant known to be resistant to all third-
generation EGFR TKIs. EAI045 and cetuximab exhibited
mechanistic synergy. EAI045 represents a novel selective
inhibitor that can overcome T790M and C797S resist-
ance mutations [21].
Discussion
C797S mutation in the EGFR gene was found to confer
resistance clinically to third-generation TKIs, AZD9291
and HM61713. This likely represents a tertiary acquired
mutation that mediates resistance to all known third-
generation EGFR TKIs. Some cases were found to har-
bor two independent clones of C797S mutation, while
others even became T790M negative, indicating the het-
erogeneity of malignant cells. This remains a significant
challenge for treatment of lung cancers.
C481S mutation has been reported to mediate resist-
ance to ibrutinib, the first-in-class irreversible Bruton
tyrosine kinase (BTK) inhibitor [26–29]. Ibrutinib cova-
lently binds to the cysteine residue 481 in the BTK. This
may suggest that the change from cysteine residue to
serine may be a recurring mutation that can block in-
hibitor binding to a broad range of tyrosine kinases. Tar-
geted sequencing for cysteine residue codon mutations
may represent a new method to rapidly identify muta-
tions in other tyrosine kinases that harbor similar
cysteine-containing motif in the tyrosine kinase domain.
Since more and more TKIs targeting EGFR and ana-
plastic lymphoma kinase (ALK) mutations are being
used for NSCLC therapy [30–34], molecular testing
guidance has been established [35]. The guideline sug-
gests that lung cancer tissues are tested by PCR for
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EGFR mutations and by FISH for ALK mutations [35].
Liquid biopsy is increasingly used for cancer diagnosis
and therapy monitoring [36]. cfDNA was used for
screening of EGFR mutations. This led to the discovery
of C797S mutation [12]. This technology of testing cfDNA
is becoming an important companion tool for biomarker
analysis and facilitating drug development [37–41].
With the availability of AZD9291 for clinical treatment
of T790M-positive NSCLC, more and more resistant cases
will appear. Additional mechanisms of resistance to third-
generation TKIs, such as HER2 and MET amplification in
C797S negative cases, were identified. Loss of T790M mu-
tation was another mechanism of resistance to AZD9291
[12]. Due to the vast diversity of malignant clones, com-
bination therapy of AZD9291 with other agents will be
needed to overcome the spectrum of resistant clones [42].
AZD9291 in combination with MET inhibitors or MEK
inhibitors is being explored (NCT02143466). Immune
checkpoint blockers have been shown to be active in a
broad range of malignancies [43–51]. Combination of
AZD9291 and PD-L1 antibody is underway in the multi-
arm phase Ib study (NCT02143466). Finally, through pur-
posefully targeting allosteric sites in the EGFR tyrosine
kinase domain and screening a vast library of compounds
that selectively target the resistant EGFR mutant, a highly
selective inhibitor, EAI045, has been discovered.
Conclusions
EGFR C797S mutation mediates resistance to third-
generation TKIs, AZD9291 and HM61713. Additional
mechanisms of resistance are being identified. Combin-
ation therapy of AZD9291 with other agents may be one
way to overcome the acquired mutation. EAI045 repre-
sents a purposefully designed selective inhibitor over-
coming EGFR C797S mutation.
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